Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia

No abstract is available for this paper.

• Publication year

  2019

• Venue

  World Journal of Biological Psychiatry

• Publication date

  2019-01-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/15622975.2017.1301681PMID 28394697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacogenetics of tardive dyskinesia: an updated review of the literature.

  2016cited by this paper
• Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway

  2016cited by this paper
• Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.

  2013cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Neuregulin-1 signalling and antipsychotic treatment

  2013cited by this paper
• Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis

  2012cited by this paper
• Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients and 45 Tag SNPs in 7 Candidate Genes: A Prospective Study

  2012cited by this paper
• Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy

  2012cited by this paper
• NMDA receptor genotypes associated with the vulnerability to develop dyskinesia

  2012cited by this paper
• Systemic administration of neuregulin‐1β1 protects dopaminergic neurons in a mouse model of Parkinson’s disease

  2011cited by this paper
• Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia

  2011cited by this paper
• Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.

  2011cited by this paper
• The catechol-O-methyl-transferase gene in tardive dyskinesia

  2010cited by this paper
• Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia.

  2009cited by this paper
• Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

  2009cited by this paper
• Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 'knockout' mice.

  2009cited by this paper
• Behavioral and Brain Functions

  2008cited by this paper
• Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors

  2008cited by this paper
• Likelihood-Based Association Analysis for Nuclear Families and Unrelated Subjects with Missing Genotype Data

  2008influential reference
• Neuregulin 1 in neural development, synaptic plasticity and schizophrenia

  2008cited by this paper
• Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study.

  2008cited by this paper
• Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients

  2007cited by this paper
• Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia.

  2007cited by this paper
• Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.

  2007cited by this paper
• Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease.

  2006cited by this paper
• Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia

  2006influential reference
• Regulation of NMDA Receptors by Neuregulin Signaling in Prefrontal Cortex

  2005cited by this paper
• Haploview: analysis and visualization of LD and haplotype maps

  2005influential reference
• Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix

  2005influential reference
• Neuregulin genotype and medication response in Finnish patients with schizophrenia

  2004cited by this paper
• A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.

  2004cited by this paper
• Neuregulin 1 and susceptibility to schizophrenia.

  2002cited by this paper
• Familial occurrence of tardive dyskinesia

  2001cited by this paper
• Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?

  2000cited by this paper
• Familial occurrence of tardive dyskinesia.

  1998cited by this paper
• GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats

  1994cited by this paper
• An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.

  1993cited by this paper
• A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies.

  1991cited by this paper
• Research diagnoses for tardive dyskinesia.

  1982cited by this paper
• Familial tardive dyskinesia.

  1981cited by this paper

• Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies

  2022cites this paper
• Pharmacogenetics of antipsychotics: Clinical utility and implementation.

  2020cites this paper
• Candidate genes involved in the development of antipsychotic-induced tardive dyskinesia in patients with schizophrenia

  2020cites this paper
• Investigation of the HSPG2 Gene in Tardive Dyskinesia – New Data and Meta-Analysis

  2018cites this paper
• Future directions in tardive dyskinesia research.

  2018cites this paper
• Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications

  2018cites this paper
• Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials.

  2018cites this paper
• Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia.

  2018cites this paper